Personalized medication plans to reduce opioid use in acute musculoskeletal pain
Official title: Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain. Multicenter, Randomized, Controlled Study
Run by University Hospital, Rouen · NCT05905146 · Data updated 2026-11-12
This study tests whether a personalized medication plan can help hospitalized patients with severe muscle and joint pain use fewer strong opioids and lower their risk of dependence compared to standard treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University Hospital, Rouen Academic / other |
| Locations | 3 sites (Lille and 2 other locations) |
| Status | Recruiting |
| Started | January 18, 2024 |
| Main results expected | July 18, 2028 |
| Study ends | July 18, 2028 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT05905146 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are hospitalized patients with acute non-cancer musculoskeletal pain who are starting or maintaining strong opioid treatment.
✕Probably not a fit
Patients with cancer, fibromyalgia, or those who have been on strong opioids for more than 30 days prior to inclusion will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of a personalized pharmaceutical plan (PPP) for patients hospitalized with acute non-cancer musculoskeletal pain. The PPP aims to inform and sensitize patients, potentially leading to a shorter duration of treatment with potent opioids and a reduced risk of dependence. Patients receiving the PPP will be compared to those managed under standard treatment protocols in rheumatology services. The study focuses on patients who are newly prescribed strong opioids or have had a prescription maintained for a limited duration.
Why it matters
Potential benefit: If successful, this approach could lead to safer opioid prescribing practices and improved pain management for patients.
How similar studies have gone: While personalized medication plans are gaining attention, this specific approach to reducing opioid use in acute musculoskeletal pain is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient hospitalized in the rheumatology department * Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology * Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion Exclusion Criteria: * Patient with cancer or fibromyalgia already diagnosed at inclusion * Patient with poor French language skills * Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion * Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment * Patient already included in the study
Where it's running
-
CHU de Lille
Lille, France Recruiting -
CHU de Nimes
Nîmes, France Recruiting -
CHU de ROUEN
Rouen, France Recruiting
Study contacts
- Principal investigator: Catherine CHENAILLER — University Hospital, Rouen
- Study coordinator: Catherine CHENAILLER
- Email: catherine.chenailler@chu-rouen.fr
- Phone: +3323288
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.